Research and Development
Our contribution to address patients’ unmet medical needs
DIATHEVA is passionate about the best science. We are a fully integrated company active in the research and development of novel biologic therapeutics in the oncology and infectious diseases areas. Our aspiration is to improve quality of life and bring health and a better future to patients, through highly innovative therapeutic solutions.
Our portfolio of innovative therapeutic molecules
A novel, first-in-class fully human recombinant antibody for the treatment of CD99 positive tumors.
|Ewing’s sarcoma (EWS), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS)|
A novel fully human recombinant antibody and immune checkpoint inhibitor for the treatment of CEACAM1 positive tumors.
A novel, first-in-class humanized antibody for the treatment of fungal infections, overcoming conventional drug resistance.